CindyA Posted January 27, 2015 Share Posted January 27, 2015 Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non–small cell lung cancer (NSCLC), following their initial debut in 2012.In the past 4 months alone, the PD-1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) have each gained separate approvals as treatments for patients with advanced melanoma. Additionally, in mid-January, phase III findings from the CheckMate-017 study demonstrated that nivolumab extended overall survival compared with docetaxel in patients with pretreated squamous cell NSCLC.Based on these findings and those from phase II studies, Bristol-Myers Squibb (BMS) is currently in the process of submitting a New Drug Application to the FDA for nivolumab as a third-line treatment for patients with squamous cell NSCLC. Furthermore, several phase III studies are currently examining the agent across a variety of tumor types.Julie R. Brahmer, MD, and Suzanne L. Topalian, MD, presented seminal research on PD-1/PD-L1 inhibition at the 2012 ASCO Annual Meeting. Results from these studies laid the foundation for future advances and shaped the development of PD-1 inhibition in cancer.In an interview, Brahmer, the interim director of the Sidney Kimmel Comprehensive Cancer Center, spoke with OncLive about the rapid development of PD-1/PD-L1 inhibition and her thoughts on the future of this novel treatment approach. - See more at: http://www.onclive.com/web-exclusives/Brahmer-Expects-Rapid-Approval-for-First-PD-1-Inhibitor-in-Lung-Cancer?utm_source=twitterfeed&utm_medium=twitter#sthash.Z9AdLFqa.whBiAwDH.dpuf Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.